Jump to content
Content on WikiMesothelioma is reviewed prior to publication by three named attorneys at Danziger & De Llano LLP. Dr. Luciano Mutti, MD, PhD, co-author of the European mesothelioma treatment guidelines, serves as the site's Medical Reviewer. See our editorial standards.

Dr. Luciano Mutti

From WikiMesothelioma — Mesothelioma Knowledge Base
Prof. Luciano Mutti, MD, PhD
Medical Reviewer, WikiMesothelioma
Specialty Medical Oncology; Respiratory Medicine
Institution UniCamillus, Rome; Temple University, Philadelphia
Key Contribution Co-author, European mesothelioma guidelines
Publications 253
Citations 7,224
h-index 47
Research Focus Mesothelioma (76% of published work)
Leadership President, GIMe (Italian Mesothelioma Group)
Free Case Review →

Executive Summary

Prof. Luciano Mutti is an Italian medical oncologist and respiratory physician who has studied malignant mesothelioma continuously since 1993 and serves as Medical Reviewer for WikiMesothelioma. He is a named author of the European clinical guidelines for the management of malignant pleural mesothelioma — the standard of care that governs how the disease is treated across Europe — appearing on both the 2009/2010 European Respiratory Society and European Society of Thoracic Surgeons guidelines and the 2020 four-society revision.[1][2]

His published record comprises 253 works cited more than 7,200 times, with an h-index of 47.[3] Mesothelioma and asbestos-related disease account for roughly 76% of that output — an unusually concentrated specialisation in a cancer that represents a small fraction of global cancer diagnoses. He was a co-author of the 2013 Lancet Oncology trial of tremelimumab in chemotherapy-resistant mesothelioma, an early test of immune checkpoint blockade in the disease conducted years before dual immunotherapy became the first-line standard.[4]

Prof. Mutti is Professor of Oncology at UniCamillus – Saint Camillus International University of Health Sciences in Rome and Adjunct Professor of Translational Oncology at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University in Philadelphia.[5][6] He is President of GIMe, the Italian Mesothelioma and Environmental Oncology Group, a registered non-profit that funds research fellowships and through which he provides free consultations to mesothelioma patients and their families.[7][8]

At a Glance

  • Co-author of the European mesothelioma treatment guidelines — named on both the 2009/2010 ERS/ESTS guidelines and the 2020 ERS/ESTS/EACTS/ESTRO revision, the documents European oncologists follow when treating this disease[1][2]
  • More than three decades of continuous mesothelioma research — his first published work on asbestos-related disease appeared in 1993, and he has published continuously since[3]
  • 253 publications cited over 7,200 times — with an h-index of 47 and an i10-index of 118[3]
  • Roughly 76% of his research is mesothelioma-specific — 196 of 257 verified publication records address mesothelioma or asbestos-related disease, a rare degree of concentration on a rare cancer[3]
  • Co-author of an early immune checkpoint inhibitor trial in mesothelioma — the 2013 Lancet Oncology tremelimumab study, published seven years before checkpoint immunotherapy became first-line standard of care[4]
  • First author of the field's 2018 state-of-the-science review — Scientific Advances and New Frontiers in Mesothelioma Therapeutics in the Journal of Thoracic Oncology, written with leading mesothelioma researchers worldwide[9]
  • Organised the 7th International Mesothelioma Interest Group congress — the field's principal international meeting, held in Brescia in 2004 with 350 participants[10]
  • Clinical experience across three national health systems — Italy, the United Kingdom and Ireland, including consultant posts at Oxford University Hospitals, North Middlesex University Hospital in London, and St James's Hospital in Dublin[5]
  • Still actively publishing — 47 publications appeared between 2023 and 2026[3]
  • Provides free consultations to patients through GIMe — the non-profit he leads offers no-cost medical consultations to mesothelioma patients and families in Italy and across Europe[8]
  • Invited faculty at the 2026 Weinman Symposium — University of Hawai'i Cancer Center, alongside researchers including Antoni Ribas and Harvey Pass[11]

Key Facts

Metric Detail
Medical Degree MD with honours, University of Genoa (1982)
Doctorate PhD in Oncology, University of Turin (1994)
Specialist Registration Medical Oncology, Royal College of Physicians of Ireland (2012)
Current Academic Post Professor of Oncology, UniCamillus, Rome
U.S. Appointment Adjunct Professor, Sbarro Institute, Temple University
Total Publications 253
Total Citations 7,224
h-index / i10-index 47 / 118
Mesothelioma-Specific Works 196 of 257 verified records (approximately 76%)
Guideline and Consensus Authorships 8
Research Career Span 1993–present (34 years)
Leadership Role President, GIMe (Italian Mesothelioma and Environmental Oncology Group)

Publication and citation metrics from OpenAlex, retrieved 12 August 2026. Citation counts change over time and differ between databases. Two denominators are used deliberately: 253 works and 7,224 citations are the OpenAlex author-profile totals, while subject and authorship breakdowns are computed over a 257-record verified publication table compiled from PubMed and OpenAlex (which counts corrections and errata as separate records).

Who Is Dr. Luciano Mutti and Why Does He Review WikiMesothelioma's Medical Content?

Prof. Luciano Mutti is a medical oncologist and respiratory physician who has spent his career on a single rare cancer. Mesothelioma accounts for a small fraction of cancer diagnoses worldwide, and few physicians build an entire research programme around it. Prof. Mutti is one of those few: 196 of the 257 records in his verified publication table address mesothelioma or asbestos-related disease — roughly 76%.[3]

He graduated in medicine with honours from the University of Genoa, his home city, in 1982, completed specialist training in respiratory medicine there in 1988, and took a PhD in oncology at the University of Turin in 1994.[5][12] In 2012 he was entered on the Specialist Register for Medical Oncology of the Royal College of Physicians of Ireland.[5]

That combination — a respiratory physician who became a medical oncologist and then a laboratory researcher — matters for mesothelioma specifically. The disease presents as a breathing problem before it is recognised as a cancer, and its first sign is often pleural effusion, fluid collecting around the lung. A physician trained in both respiratory medicine and oncology sees the whole arc of the illness.

As WikiMesothelioma's Medical Reviewer, Prof. Mutti reviews medical content on this site for accuracy before publication. His review covers medical accuracy only.

ℹ️ What a medical reviewer does: A medical reviewer checks that the clinical claims on a page reflect the current published evidence — that survival figures match their source studies, that treatments are described as their trials actually reported them, and that nothing overstates what the evidence supports. Review is not a substitute for advice from your own treating physician.

What Are Dr. Mutti's Most Significant Research Contributions?

Co-authorship of the European treatment guidelines

Prof. Mutti's most consequential credential is his participation in the European clinical guidelines for malignant pleural mesothelioma. He is a named author of the 2009/2010 guidelines issued jointly by the European Respiratory Society and the European Society of Thoracic Surgeons,[1] and of the 2020 revision produced by four European societies — the ERS, ESTS, the European Association for Cardio-Thoracic Surgery, and the European Society for Radiotherapy and Oncology.[2]

These are the documents European oncologists consult when deciding how to treat a mesothelioma patient. The 2009/2010 guideline is his most-cited work, with 638 citations.

Guideline or Consensus Document Year PMID
ERS/ESTS guidelines for malignant pleural mesothelioma 2009/2010 19717482
ERS/ESTS/EACTS/ESTRO guidelines for malignant pleural mesothelioma 2020 32451346
ERS statement on harmonised lung cancer standards in Europe 2018 30361252
Surgery for malignant pleural mesothelioma: international guidelines review 2018 29507797
ERS guideline on quality in lung cancer care 2023 36396145

Early work on immunotherapy for mesothelioma

Long before immunotherapy became standard mesothelioma treatment, Prof. Mutti's laboratory was studying how the immune system responds to the tumour. As first author, he published evidence that mesothelioma cells can present antigens to a patient's own immune cells — meaning the tumour is visible to the immune system — while his group simultaneously showed those same cells suppress the response through TGF-beta signalling.[13][14]

That finding supplied a rationale for releasing the brake on the immune response, and he was a co-author of the resulting 2013 trial of tremelimumab — a CTLA-4 checkpoint inhibitor — in patients whose mesothelioma had stopped responding to chemotherapy, published in Lancet Oncology.[4] The trial was conducted years before the CheckMate 743 study established dual checkpoint immunotherapy as first-line treatment, and Prof. Mutti describes it as the first trial of an immune checkpoint inhibitor conducted in this disease.

Establishing VEGF as a target in mesothelioma

In 2001 his group reported in the Journal of Pathology that vascular endothelial growth factor (VEGF) acts as an autocrine growth factor in mesothelioma — that the tumour produces a signal driving its own blood supply and its own growth.[15] The paper has been cited 345 times and belongs to the body of evidence behind the antiangiogenic drugs now written into mesothelioma treatment guidelines.

Serum mesothelin as a biomarker

Prof. Mutti contributed to research establishing serum mesothelin as a clinically useful biomarker in mesothelioma — a blood measurement used as an adjunct in diagnosis and in monitoring patients during follow-up.[16]

Leading the field's state-of-the-science review

In 2018 Prof. Mutti was first author of Scientific Advances and New Frontiers in Mesothelioma Therapeutics in the Journal of Thoracic Oncology, written with a group of the field's leading investigators including Bruce Robinson, Arnaud Scherpereel, Michele Carbone and Raffit Hassan.[9] Leading that review means his peers looked to him to summarise where mesothelioma treatment stood.

Organising the field's international conference

In 2004 Prof. Mutti organised the 7th international meeting of the International Mesothelioma Interest Group (IMIG), held in Brescia, Italy, together with G.F. Tassi. The conference — "How advanced technology and new drugs are changing the perspectives of patients with malignant mesothelioma" — drew 350 participants, and he was first author of the meeting review published in Oncogene with V. Courtney Broaddus.[10][17]

IMIG is the principal international forum for mesothelioma research, and its biennial congress is where the field's investigators present new work. Being asked to host and organise it is a marker of standing among peers.

A voice for rigour in how trials are reported

A recurring theme in Prof. Mutti's recent writing is scepticism about how mesothelioma trial results are presented to patients and clinicians. He has published critical analyses of frontline therapy trials in JAMA Network Open,[18] and has questioned whether reported immunotherapy benefits hold up in real-world practice.[19] This is directly relevant to his review role: the risk to patients reading about mesothelioma online is not usually outright falsehood but overstatement, and his published work is concerned with exactly that.

What Is Dr. Mutti's Clinical and Academic Background?

Current appointments

  • Professor of Oncology, UniCamillus – Saint Camillus International University of Health Sciences, Rome (2025–present)[5]
  • Adjunct Professor of Translational Oncology, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia (2018–present)[20]
  • President, GIMe — Gruppo Italiano Mesotelioma e Oncologia Ambientale[21]

Previous academic posts

  • Professor of Oncology, University of L'Aquila (2022–2025)
  • Chair in Cancer Research, University of Salford, Manchester (2014–2018)[5]

Clinical practice

Prof. Mutti has practised across three national health systems. In Italy he led the Department of General Medicine and directed the translational research unit in thoracic medical oncology at Vercelli Teaching Hospital from 1999 to 2014, and later headed the Department of Medical Oncology at S. Salvatore Hospital in L'Aquila and directed the ASL1 Abruzzo oncology network (2022–2025). In the United Kingdom and Ireland he held consultant posts in medical oncology at Oxford University Hospitals, North Middlesex University Hospital in London, and St James's Hospital in Dublin.[5]

He retired from the Italian public university system and the National Health Service in November 2025 and continues teaching, research and clinical work.[5]

How Does Dr. Mutti Work Directly With Mesothelioma Patients?

Prof. Mutti is President of GIMe (Gruppo Italiano Mesotelioma e Oncologia Ambientale), an Italian registered non-profit founded by researchers that funds fellowships for young scientists and laboratory equipment, and which states its independence from commercial interests.[8]

Through GIMe he offers free medical consultations to mesothelioma patients and their families.[8] For European patients and families, GIMe is a direct point of contact with a specialist in this disease.

ℹ️ For patients in Europe: GIMe provides free consultations with mesothelioma specialists in Italy. Patients and families can reach the organisation at landing.gime.it.

What Recognition Has Dr. Mutti Received?

  • Invited faculty, XVII Barry & Virginia Weinman Symposium, University of Hawai'i Cancer Center, January 2026 — appearing alongside researchers including Antoni Ribas and Harvey Pass[11]
  • National Fair Play Award for Scientific Research (2019) — conferred by the Comitato Nazionale Italiano Fair Play under the patronage of the Italian National Olympic Committee[22]
  • Organiser, 7th International Mesothelioma Interest Group congress (Brescia, Italy, 2004) — 350 participants; first author of the meeting review in Oncogene[10]
  • Member, IASLC task force on new therapeutic targets for malignant pleural mesothelioma
  • Editorial board member, Frontiers in Oncology and Biomedicines
  • Court-appointed technical expert (CTU) in major Italian asbestos proceedings, including the La Scala, Pirelli and Corriere della Sera cases, acting on behalf of exposed workers[23]

Selected Publications

Prof. Mutti has published 248 indexed works cited more than 7,200 times (OpenAlex, retrieved 2026-08-31). The following are grouped by research thread. Author order is preserved exactly as published — where he is not the first author his position is stated, never moved forward.

European treatment guidelines

  1. Scherpereel A, Astoul P, Baas P, et al. (incl. Mutti L, author 12 of 18). Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. European Respiratory Journal 2010;35(3):479-95. PMID 19717482
  2. Scherpereel A, Opitz I, Berghmans T, et al. (incl. Mutti L, author 23 of 30). ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. European Respiratory Journal 2020;55(6). PMID 32451346
  3. Ricciardi S, Cardillo G, Zirafa CC, et al. (incl. Mutti L, author 7 of 8). Surgery for malignant pleural mesothelioma: an international guidelines review. Journal of Thoracic Disease 2018;10(Suppl 2):S285-S292. PMID 29507797

SV40 and viral co-carcinogenesis

  1. Cacciotti P, Libener R, Betta P, et al. (incl. Mutti L, author 10 of 11). SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proceedings of the National Academy of Sciences 2001;98(21):12032-7. PMID 11572935
  2. Cristaudo A, Foddis R, Vivaldi A, et al. (incl. Mutti L, author 15 of 16). SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Research 2005;65(8):3049-52. PMID 15833832
  3. Cacciotti P, Barbone D, Porta C, et al. (incl. Mutti L, author 6 of 7). SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Research 2005;65(12):5256-62. PMID 15958571

Mineral fibre carcinogenesis

  1. Bertino P, Marconi A, Palumbo L, et al. (incl. Mutti L, author 10 of 11). Erionite and asbestos differently cause transformation of human mesothelial cells. International Journal of Cancer 2007;121(1):12-20. PMID 17354240
  2. Neri M, Ugolini D, Dianzani I, et al. (incl. Mutti L, author 8 of 10). Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases. Mutation Research 2008;659(1-2):126-36. PMID 18420450

Biomarkers and molecular diagnostics

  1. Strizzi L, Catalano A, Vianale G, et al. (incl. Mutti L, author 8 of 9). Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. Journal of Pathology 2001;193(4):468-75. PMID 11276005
  2. Cristaudo A, Foddis R, Vivaldi A, et al. (incl. Mutti L, author 15 of 16). Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clinical Cancer Research 2007;13(17):5076-81. PMID 17785560
  3. Busacca S, Germano S, De Cecco L, et al. (incl. Mutti L, author 8 of 10). MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. American Journal of Respiratory Cell and Molecular Biology 2010;42(3):312-9. PMID 19502386

Estrogen receptor biology

  1. Pinton G, Brunelli E, Murer B, et al. (incl. Mutti L, author 8 of 9). Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Research 2009;69(11):4598-604. PMID 19487281
  2. Pinton G, Thomas W, Bellini P, et al. (incl. Mutti L, author 7 of 8). Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib. PLoS ONE 2010;5(11):e14110. PMID 21124760

BAP1 and treatment sensitivity

  1. Guazzelli A, Meysami P, Bakker E, et al.; Mutti L (last author). BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment. International Journal of Molecular Sciences 2019;20(2). PMID 30669483

Immunotherapy and trial methodology

  1. Calabrò L, Morra A, Fonsatti E, et al. (incl. Mutti L, author 10 of 11). Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncology 2013;14(11):1104-1111. PMID 24035405
  2. Mutti L, Peikert T, Robinson BWS, et al. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. Journal of Thoracic Oncology 2018;13(9):1269-1283. PMID 29966799
  3. Gray SG; Mutti L (last author). Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. Translational Lung Cancer Research 2020;9(Suppl 1):S100-S119. PMID 32206576
  4. Meirson T, Pentimalli F, Cerza F, et al.; Mutti L (last author). Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma. JAMA Network Open 2022;5(3):e221490. PMID 35262715
  5. Belli C, Gray SG, Masedu F; Mutti L (last author). Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743. Journal of Clinical Oncology 2026 (online ahead of print). PMID 42430689

A complete bibliography is available through his ORCID record and via PubMed.

Frequently Asked Questions

Who is Dr. Luciano Mutti?

Prof. Luciano Mutti is an Italian medical oncologist and respiratory physician who has researched malignant mesothelioma since 1993. He is Professor of Oncology at UniCamillus in Rome and Adjunct Professor of Translational Oncology at Temple University in Philadelphia, and he serves as Medical Reviewer for WikiMesothelioma.

What are Dr. Mutti's medical qualifications?

He holds an MD with honours from the University of Genoa (1982), specialist training in respiratory medicine from the same university (1988), and a PhD in oncology from the University of Turin (1994). In 2012 he was entered on the Specialist Register for Medical Oncology of the Royal College of Physicians of Ireland.

What is Dr. Mutti best known for in mesothelioma research?

He is best known as a co-author of the European clinical guidelines for the management of malignant pleural mesothelioma, published in 2009/2010 and revised in 2020. He was also a co-author of the 2013 Lancet Oncology tremelimumab trial, an early test of immune checkpoint immunotherapy in mesothelioma, and first author of the field's 2018 state-of-the-science review of mesothelioma therapeutics.

What role has Dr. Mutti played in the international mesothelioma research community?

He organised the 7th international congress of the International Mesothelioma Interest Group (IMIG), held in Brescia, Italy in 2004 and attended by 350 researchers and clinicians, and was first author of the meeting review published in Oncogene. IMIG is the principal international forum for mesothelioma research. He has been active in the organisation since the 1990s and has described himself as one of the group of researchers involved in its formation.

How much of Dr. Mutti's research is about mesothelioma?

Approximately 76% — 196 of the 257 records in his verified publication table address mesothelioma or asbestos-related disease. His research career on this cancer spans from 1993 to the present, and he published 47 works between 2023 and 2026.

What does it mean that Dr. Mutti reviews WikiMesothelioma's medical content?

It means a physician who specialises in mesothelioma checks the site's medical pages for accuracy before they are published — confirming that the clinical claims match the published evidence they cite. His review addresses medical accuracy only and is not an endorsement of any legal service. Reviewed pages carry a dated review byline.

Can mesothelioma patients consult Dr. Mutti?

Through GIMe, the Italian mesothelioma non-profit he leads, Prof. Mutti provides free medical consultations to mesothelioma patients and families. GIMe can be contacted at landing.gime.it. Patients should continue to work with their own treating oncologist for decisions about their care.

Where can I verify Dr. Mutti's publication record?

His complete publication record is available through his ORCID record (0000-0002-1578-2637), through PubMed, and through OpenAlex. The citation metrics on this page come from OpenAlex and were retrieved on 12 August 2026.

Quick Statistics

  • 253 — Total published works
  • 7,224 — Total citations of his published research
  • 47 — h-index
  • 118 — i10-index
  • 196 — Publications addressing mesothelioma or asbestos-related disease
  • 76% — Share of his verified publication record devoted to mesothelioma (196 of 257)
  • 8 — Clinical guideline and consensus documents he has co-authored
  • 47 — Publications between 2023 and 2026
  • 34 years — Span of his mesothelioma research career, from 1993 to the present
  • 3 — National health systems in which he has practised (Italy, United Kingdom, Ireland)

Bibliometric data from OpenAlex, retrieved 12 August 2026.

Medical Review Disclosure

Disclosure: Prof. Luciano Mutti serves as Medical Reviewer for WikiMesothelioma, reviewing medical content for accuracy prior to publication. He is compensated for this review work. His review covers medical accuracy only and does not constitute an endorsement of any legal service or law firm. Prof. Mutti is not an author of WikiMesothelioma content and does not review the site's legal content. Pages he has reviewed carry a dated review byline and are listed in Category:Medically Reviewed. See Editorial Standards for the site's full editorial process.

Prof. Mutti has served as a court-appointed technical expert (CTU) in Italian asbestos proceedings on behalf of exposed workers, and as a party-appointed expert (CTP) in exposure, malpractice and compensation matters. This history is disclosed in the interest of transparency.

Get Help

If you or a loved one has been diagnosed with mesothelioma after asbestos exposure, you may be entitled to compensation from asbestos trust funds and legal claims. Understanding your diagnosis and treatment options is an essential part of navigating what comes next.

Danziger & De Llano represent mesothelioma patients and their families in claims for medical expenses, lost wages, and pain and suffering. Contact details are available on the firm's own site.

For help finding an attorney near you, visit Mesothelioma Lawyers Near Me. For additional patient and family resources, visit Mesothelioma.net.

References

  1. ↑ 1.0 1.1 1.2 Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma, European Respiratory Journal 2010;35(3):479-95. PMID 19717482
  2. ↑ 2.0 2.1 2.2 ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma, European Respiratory Journal 2020;55(6):1900953. PMID 32451346
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Luciano Mutti — author record, OpenAlex. Retrieved 12 August 2026.
  4. ↑ 4.0 4.1 4.2 Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial, Lancet Oncology 2013;14(11):1104-1111. PMID 24035405
  5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 Luciano Mutti — Lecturer profile, UniCamillus – Saint Camillus International University of Health and Medical Sciences
  6. ↑ Luciano Mutti — Directory, Temple University College of Science and Technology
  7. ↑ Chi siamo, Gruppo Italiano Mesotelioma e Oncologia Ambientale (GIMe)
  8. ↑ 8.0 8.1 8.2 8.3 GIMe ETS — "il nostro presidente Luciano Mutti, professore di oncologia, è a disposizione per consulenze mediche gratuite"
  9. ↑ 9.0 9.1 Scientific Advances and New Frontiers in Mesothelioma Therapeutics, J Thorac Oncol 2018;13(9):1269-1283. PMID 29966799
  10. ↑ 10.0 10.1 10.2 Malignant mesothelioma as both a challenge and an opportunity, Oncogene 2004;23(57):9155-61. PMID 15516978
  11. ↑ 11.0 11.1 XVII Weinman Symposium programme, University of Hawai'i Cancer Center
  12. ↑ Luciano Mutti — Directory, Temple University College of Science and Technology
  13. ↑ Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes, PMID 9833768
  14. ↑ Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis, Int J Mol Med 2003;11(2):161-7. PMID 12525871
  15. ↑ Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma, J Pathol 2001;193(4):468-75. PMID 11276005
  16. ↑ Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer, Clinical Cancer Research 2007;13(17):5076-81. PMID 17785560
  17. ↑ Malignant mesothelioma in 2004: Highlights from the VIIth Meeting of the International Mesothelioma Interest Group, Med Lav 2005;96(4):360-9. PMID 16457433
  18. ↑ Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma, JAMA Netw Open 2022;5(3):e221490. PMID 35262715
  19. ↑ Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma, J Thorac Oncol 2024;19(4):541-546. PMID 38582546
  20. ↑ Luciano Mutti — Directory, Temple University College of Science and Technology
  21. ↑ Chi siamo, GIMe
  22. ↑ Premi Nazionali Fair Play, ONA Notiziario Amianto
  23. ↑ Curriculum — Luciano Mutti, GIMe


Retrieved from "https://wikimesothelioma.com/w/index.php?title=Dr._Luciano_Mutti&oldid=4558"